Medical devices, healthcare technology and the business of care
PMA approval · P190002

Saluda Medical Evoke SCS System

Saluda Medical Pty, Ltd. · Decision date Feb 28, 2022

FDA DECISIONP190002

What did the FDA approve?

FDA records P190002 as an original PMA application. The recorded decision is approval, dated Feb 28, 2022.

FDA approval order statement

Approval for the Evoke SCS System. This device is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbsincluding unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Feb 28, 2022

FDA source record

Regulatory record facts

Identifier
P190002
Regulatory pathway
Premarket approval application
Product code
LGW
Decision code
APPR
Decision date
Feb 28, 2022
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.

Product code
LGW
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P190002 received

    Application receipt date recorded by FDA.

  2. P190002 · FDA decision

    APPR

  3. P190002/S051 · Related supplement

    Saluda Medical Evoke SCS System

  4. P190002/S052 · Related supplement

    Saluda Medical Evoke SCS System

Timeline entries are records held by MedtechLedger for P190002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190002

Product / regulatory recordCompanyPathwayDecision dateSource
Saluda Medical Pty, Ltd.PMA supplementOct 15, 2026FDA
Saluda Medical Pty, Ltd.PMA supplementOct 16, 2026FDA

Explore the linked device profile

Other records with product code LGW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Saluda Medical Pty, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Level 1, 407 Pacific Hwy., Atarmon, NSW 2064

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records